In vitro Effects of Biologically Active Vitamin D on Myogenesis: A Systematic Review by Alliband, Kathryn H. et al.
  
 
In vitro effects of biologically active
vitamin D on myogenesis: A Systematic
Review
 Kathryn H. Alliband1, Sofia V. Kozhevnikova1, Tim Parr1, Preeti H. Jethwa1*, John M. Brameld1
 
1School of Biosciences, Faculty of Science, University of Nottingham, United Kingdom
 Submitted to Journal:








 05 Jul 2021
 Revised on:
 05 Aug 2021





 Conflict of interest statement
 The authors declare that the research was conducted in the absence of any commercial or financial
relationships that could be construed as a potential conflict of interest
  
 Author contribution statement
 
KHA and JMB contributed to the conception and interpretation of the data and reviewing of the drafts.  KHA contributed to writing
the original draft, acquisition, and analysis of the data, SVK con-tributed to the data acquisition, TP and PHJ contributed to the









Vitamin D (VD) deficiency is associated with muscle weakness. A reduction in the incidence of falls in the elderly following VD
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1,25(OH)2D3 on proliferation was reported, while the effects on the different stages of differentiation were less consistent
probably due to variation in cell type, time points and doses of 1,25(OH)2D3 used. However myotube size was consistently
increased by 1,25(OH)2D3. Overall, the evidence suggests that 1,25(OH)2D3 inhibits proliferation and promotes differentiation of
myoblasts, but future studies should use time courses to gain a clearer understanding.
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Abstract: Vitamin D (VD) deficiency is associated with muscle weakness. A reduction in the9
incidence of falls in the elderly following VD supplementation and identification of the VD receptor10
within muscle cells suggests a direct effect of VD on muscle, but little is known about the underlying11
mechanisms. Here we systematically searched the literature to identify effects of active VD12
(1,25(OH)2D3) on skeletal muscle myogenesis in vitro, with no restriction on year of publication.13
Eligibility was assessed by strict inclusion/exclusion criteria and agreed by two independent14
investigators. Twelve relevant pa-pers were identified using four different cell types (C2C12, primary15
mouse satellite cells, primary chick myoblasts and primary human myoblasts) and a range of16
myogenic markers (myoD, myogenin, creatine kinase, myosin heavy chain and myotube size). A17
clear inhibitory effect of 1,25(OH)2D3 on proliferation was reported, while the effects on the different18
stages of differentiation were less consistent probably due to variation in cell type, time points and19
doses of 1,25(OH)2D3 used. However, myotube size was consistently increased by 1,25(OH)2D3.20
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Overall, the evidence suggests that 1,25(OH)2D3 inhibits proliferation and promotes differentiation21
of myoblasts, but future studies should use time courses to gain a clearer understanding.22
1. Introduction23
The link between vitamin D (VD) and bone health has been studied extensively, but recent evidence24
points towards a relationship between VD and skeletal muscle function [1]. Muscle biopsies from VD25
deficient individuals show muscle wasting (mostly type II fibre atrophy), large interfibrillar spaces26
and fat infiltration within the muscle [2]. In general, deficiency occurs when levels of 25(OH)D327
(inactive vitamin D) fall below 25nmol/L, however this cut-off point can vary within the literature28
[3]. In the elderly population, vitamin D deficiency has been linked to an increased risk of falls which29
is thought to be partly due to muscle weakness and wasting [4].30
Around 80-90% of VD is obtained via UV-B induced synthesis in the skin in humans, whilst 10-20%31
comes from dietary intake [3]. In the skin, 7-dehydrocholesterol is converted to pre-vitamin D upon32
UV-B radiation. This is then converted to cholecalciferol which becomes bound to VD binding33
globulin and this complex is transported to the liver where it undergoes hydroxylation by 25-34
hydroxylase to form 25(OH)D3 or calcidiol [5]. 25(OH)D3 is the major circulating form of VD and35
is measured as a marker of VD status [6]. A final step, to produce the biologically active form of VD,36
involves hydroxylation by 1α-hydroxylase to produce 1,25(OH)2D3 otherwise known as calcitriol 37
[5] (Figure 1). 1α-hydroxylase is expressed largely in the kidney, which contributes to active VD in 38
the circulation, however the enzyme is also expressed within other tissues such as muscle, which39
allows local conversion of inactive to active VD [2].40
Studies in both chicken and human skeletal muscle have identified the presence of the vitamin D41
receptor (VDR) within muscle cells thereby providing evidence for a direct effect of VD on muscle42
[7,8]. This has since been supported by human studies which have found that low serum 25(OH)D343
concentrations in elderly individuals is associated with reduced muscle strength and an increased risk44
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of falls [9]. These effects of VD deficiency on muscle appear to be reversible with supplementation45
in the elderly population leading to beneficial outcomes such as increased strength, balance, and a46
decreased risk of falls [10]. This effect is thought to be, at least in part, directly through the VDR47
present in muscle cells. VDR knockout mice have been found to have muscle fibres which are 20%48
smaller in size than controls as well as smaller body size, weight, and impaired motor co-ordination49
[6].50
Within the literature, VDRs have been described in different cell locations, one as a nuclear hormone51
receptor and the other as a membrane receptor [2]. The origin of the membrane receptor is unclear,52
some argue there is a distinct membrane receptor, however the majority of evidence points towards53
one VDR with the ability to translocate between the nucleus and membrane [3].54
It is well known that the VDR has a nuclear hormone receptor function, with the transcription of over55
900 genes found to be affected upon treatment with active VD [11]. 1,25(OH)2D3, binds to the VDR56
which induces heterodimerisation with the retinoid X receptor (RXR). This complex is then able to57
bind to VD response elements (VDREs) to activate or repress transcription of target genes [3].58
Expression of genes involved in myogenic proliferation and differentiation have been shown to59
change upon treatment with VD leading to the suggestion that VD may have a direct effect on60
myogenesis [1].61
The aim of this systematic review is to summarise the current body of evidence on the effects of62
active VD on skeletal muscle cells in culture. There is conflicting evidence in this area, therefore this63
review aims to summarise, assess, and interpret the current body of evidence and identify areas where64
further investigation is required.65
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2. Materials and Methods66
This review was constructed in accordance with the Preferred Reporting Items for Systematic67
Reviews and Meta-Analyses (PRISMA) guidelines [12].68
2.1. Search and Selection Criteria69
Relevant papers were identified through the computerised search databases (PubMed (MEDLINE),70
Web of Science and Google Scholar). The search process followed the population (P), Intervention71
(I), Comparison (C) and outcome (O, PICO). The review population was in vitro models of muscle72
cells, the intervention was active VD treatment, comparison was controls not treated with VD and the73
measuring outcomes were the effects of active VD on muscle proliferation and differentiation.74
Specific search terms ‘vitamin D OR 1,25Dihydroxyvitamin D3 OR 1,25(OH)2D3 OR calcitriol75
AND myogenesis OR muscle differentiation’ were used to obtain relevant articles. To obtain the76
relevant articles, two independent reviewers (KHA & SVK) assessed the titles, abstract and full77
articles based on a strict inclusion and exclusion criteria and if any disagreements arose, these were78
resolved by discussion. Finally, the reference list of these were searched to find any additional papers.79
2.2. Selected Articles Criteria80
Articles were not restricted to any dates as there have been no previous systematic reviews conducted81
investigating the literature relating to active VD and myogenesis in vitro.82
Inclusion Criteria83
 Studies must have been written in English to avoid any translation errors.84
 All articles must have described an in vitro model of muscle cells (primary or cell line).85
 Any form of active VD can be considered (1,25(OH)2D3 or active VD analogues).86
 Treatment of VD must be of known quantity and administered alone and not in combination with87
other drugs/vitamins/minerals.88
 Must determine effects on proliferation/differentiation of muscle cells.89
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Exclusion Criteria90
 Whole animal or human models.91
 Systematic reviews or critical reviews.92
 Studies investigating VD receptor and not VD.93
 Studies investigating cancer or ageing.94
2.3. Measured Outcomes95
The primary measured outcomes of this review are markers of myogenesis such as level of DNA96
synthesis, mRNA and protein levels of myoD, myogenin, myosin/myosin heavy chain isoforms,97
creatine kinase activity and myotube size. There were no secondary measured outcomes.98
2.4. Data extraction99
Using a standard extraction form, data from all studies were extracted and charted using Excel100
(Microsoft Excel, Washington, USA). Data extracted included title, author, publication year, muscle101
cell model used, exposure to VD and outcomes (DNA, myogenin, myoD, creatine kinase, myosin and102
myotube size).103
All key characteristics of the selected papers were expressed in tables. These included the study104
design, model used, number of samples, outcome measures and doses of VD converted to moles for105
consistency.106
2.5. Data Analysis107
The significant effects (p<0.05) in response to VD were charted to compare across the articles108
reviewed, however some values were read from graphs where raw data was not provided so are best109
estimates. Changes in expression were used to generate bar graphs using Excel (Microsoft Excel,110
Washington, USA), all changes were converted to fold-change for consistency.111
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Meta-analysis could not be carried out due to variation in methods between papers. Differences in112
cell type, time points used and concentrations of VD used meant that direct comparisons in the form113
of a meta-analysis was not possible.114
2.6. Quality Assessment115
The quality assessment method used in this review is a modified version of Risk of Bias (RoB) 2 tool116
from the Cochrane database to assess risk of bias in randomised trials. This assessment tool has been117
modified to be appropriate for cell culture experiments such as those included within this review118
(Supplementary Table 1). Responses in green indicate potential markers for a low risk of bias, orange119
indicates moderate risk and red indicates potential markers for a high risk of bias. (Y = yes, PY =120
probably yes, PN = probably no, N = no, NI = no information given or not applicable). Questions121
starting with 1 relate to risk of bias from treatment allocation. Questions starting with 2 relate to risk122
of bias in measurement of the data. Questions starting with 3 relate to risk of bias in selection of the123
reported result. Three or four questions were used to assess each section and an overall risk of bias124
was decided upon. There are three options for overall risk of bias judgement: low risk, high risk or125
some concerns.126
3. Results127
3.1. Eligibility of studies128
Using electronic databases (PubMed (MEDLINE), Web of Science and Google Scholar), we129
identified 349 articles between 1978 and 2020. The removal of duplicates and initial title screen left130
301 articles for detailed assessment. Of these 25 were evaluated against the inclusion/exclusion131
criteria. 10 of these were animal studies and 3 focused on cancer cells, ageing and VD receptor. This132
left 12 articles eligible for inclusion within this review (Figure 2). A detailed list of excluded studies133
with reasoning for exclusion can be found in Supplementary Table 2.134
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3.2. Quality Assessment135
All 12 papers received a score of ‘low risk’ when assessed against the quality assessment criteria136
previously outlined in Supplementary Table 1. For three of the studies [13-15] no information could137
be found regarding replicates and/or repeats therefore it was assumed that this was adequate when138
giving a low overall bias score (Table 1).139
3.3. Study Characteristics140
All studies included within this review used the biologically active form of VD (1,25(OH)2D3) apart141
from Saito et al, 2017 [16] where an analogue of the active form of VD called Eldecalcitol was used.142
Four different cell types were used across the studies (C2C12, primary human myoblasts, primary143
mouse satellite cells and primary chick myoblasts) and active VD concentration ranged from 10-5M144
to 10-13M (Table 2).145
3.4. Effects on Proliferation146
From the relevant articles, eight [4,13-15,17-20] studied the effects of 1,25(OH)2D3 on proliferation147
and all reported an inhibitory effect. Of these, four [13,15,18,19] quantified DNA content as a marker148
of proliferation (Figure 3). Interestingly, one study [13] reported an initial short stimulatory effect of149
1,25(OH)2D3 treatment on DNA synthesis on day 1 (1.5-fold increase) however, this was followed150
by an inhibitory effect on day 4 (0.7-fold). The remaining three studies [15,18,19] all revealed a151
decrease in DNA content of different magnitude (0.5 to 0.95-fold) (Figure 3).152
The other four studies measured proliferation in various ways (Table 3). One study showed an153
increase in p21 and p27 mRNA [17] whilst three studies revealed a decrease in cyclin mRNAs154
[14,15,19]. Decreases in proliferation was also shown by an increase in number of cells in the155
quiescent phase [14,17,18], decreased levels of proliferating cell nuclear antigen (PCNA) at the156
protein level [4] and decreases in DNA synthesis as previously reported. It is important to note that157
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only two out of eight of these studies checked for differences in apoptosis between treated and control158
cells [14,15].159
3.5. Effects on differentiation160
Differentiation of muscle cells was determined in all but one [19] of the final twelve studies. Markers161
of differentiation included expression of mRNA or protein for myoD (early differentiation),162
myogenin (early-mid stage), myosin/myosin heavy chain isoforms (late stage) or the measurement of163
creatine kinase activity (mid-stage). However, it should be noted that the mRNA expression of164
myogenin and myosin heavy chain isoforms have been shown to change during the time course of165
differentiation in C2C12 cells [21] indicating that the time point at which these markers are measured166
is important.167
3.6. Effects of vitamin D on early-stage myogenic differentiation168
Five studies measured myoD expression [4,15,16,20,22]. Three of these studies measured expression169
on day 4 [4,16,20] whilst one measured expression on day 1 [15] and another on day 7 [22] (Figure170
4). mRNA expression was measured in all cases except for one [22] where protein expression was171
measured. Four out of five studies [4,16,20,22] reported an increase in expression of myoD which172
ranged from 1.8-fold to 3-fold. However, one study [15] reported a decrease in expression of 0.5-fold173
on day 1. These changes in myoD expression were in response to 10-7M 1,25(OH)2D3 for all cases174
apart from one [16] which used 10-7M Eldecalcitol, an analogue of the active form of VD.175
3.7. Effects of vitamin D on early/mid-stage myogenic differentiation176
Myogenin expression in response to 1,25(OH)2D3 was investigated by nine of the twelve studies177
included within this review [4,14,15,17,18,20,22-24]. The time points at which myogenin expression178
was measured varied from day 1 to day 7. For eight of the nine studies which measured myogenin,179
the concentration of 1,25(OH)2D3 used was 10-7M but one study [23] used 10-8M 1,25(OH)2D3. In180
most cases mRNA expression was measured but in two studies [22,23] protein expression was181
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measured. Unlike myoD expression, the level of agreement between studies relating to myogenin182
expression was low with five studies reporting a decrease in myogenin expression [14,15,17,20,24]183
and four studies reporting an increase in expression [4,18,22,23] (Figure 5).184
Three studies measured creatine kinase activity as a marker of differentiation [13,23,24]. Two of these185
studies reported their results as a time course [13,23] whilst one reported results for day 4 only [24].186
A variety of concentrations of 1,25(OH)2D3 were used across the studies (Table 4). One study [24]187
reported results for cells grown in either myogenic media or adipogenic media, but only the results188
for myogenic media have been used to allow comparison to the other studies. Two studies reported189
an increase in creatine kinase activity which peaked on day 2 following 1,25(OH)2D3 treatment190
[13,23] whilst the other study found that creatine kinase activity decreased across all 1,25(OH)2D3191
concentrations on day 4 [24].192
3.8. Effects of vitamin D on late-stage myogenic differentiation193
A total of seven studies investigated the effects of 1,25(OH)2D3 treatment on myosin protein or194
mRNA/protein levels of myosin heavy chain (MyHC) isoforms, with the majority measuring the latter195
[15-18,20,23]. MyHC neonatal (MyHC neo) and type IIa (MyHCIIa) were the most commonly196
studied isoforms across the papers. Time points of expression varied greatly between studies. In some197
cases, expression was measured as early as day 1 whereas others measured up to day 8 (Table 5).198
Overall, one study found an increase in myosin protein [13], one study found and increase in MyHC199
protein [23], three studies reported an increase in expression of at least one MyHC isoform200
[16,17,20,23] and two studies reported a decrease in MyHC isoforms (MyHC neo, MyHC IIa and201
MyHCII subtype unspecified) [15,18].202
Five studies measured the effects of 1,25(OH)2D3 on myotube size [4,14,18,20,23] (Figure 6). This203
was also measured at varying time points from day 2 to day 10. For one study 10-9M 1,25(OH)2D3204
was used [23] whilst 10-7M 1,25(OH)2D3 was used in the other four [4,14,18,20]. All five studies205
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concluded that treatment with 1,25(OH)2D3 resulted in an increase in myotube size which ranged206
from 1.1-fold to 2-fold.207
4. Discussion208
This review has shown good agreement across the different studies in terms of the active form of VD209
inhibiting muscle cell proliferation. However, the effects on differentiation, as determined by various210
markers, showed less consistency, probably due to a combination of different cell types and time211
points being used.212
4.1. Treatment with vitamin D inhibits proliferation.213
Of the eight studies which investigated the effects of active VD on muscle cell proliferation214
[4,13-15,17-20], all of them found an inhibitory effect. One study observed a stimulatory effect on215
day 1, however this was followed by inhibition on day 4 [13]. It is worth noting that only two studies216
[14,15] checked for differences in apoptosis between treated and untreated groups therefore it cannot217
be ruled out that the decrease in DNA observed in some of the other studies was not due to apoptosis.218
Importantly, Okuno et al, 2012 [17] showed that active VD caused an increase in cell cycle arrest at219
G0/G1 which occurred in parallel with increased expression of p21 and p27. Both p21 and p27 are220
members of the Cip/Kip family and are able to bind to cyclin dependent kinases and inhibit their role221
in cell cycle progression [25]. In order for a cell to proliferate, expression of p21 must decrease to a222
level where it no longer forms a complex with p53 [26]. Additionally, cells must also reduce/eliminate223
p27 to progress through proliferation, which is achieved via translocation of p27 to the cytoplasm224
where it is degraded [25]. Both Okuno et al, 2012 [17] and Olsson et al, 2016 [15] reported increased225
expression of both p21 and p27 suggesting that active VD treatment leads to increased transcription226
of these factors which likely contributes to the inhibition of cell proliferation.227
In rev
ie
Vitamin D deficiency and Muscle myogenesis
11
Two studies reported that active VD decreased expression of both cyclin A2 and cyclin D3 [15,19].228
Cyclin A2 is able to bind to and activate two cyclin dependent kinases (CDKs) required for cell cycle229
progression: CDK4 as DNA synthesis begins during S phase and CDK1 during the transition from230
G2 to M phase [27]. The D cyclins activate CDK4/6 enabling entry into S phase and down-regulation231
of cyclin D3 specifically inhibits G1 to S transition [28]. From this, it can be suggested that active232
VD represses transcription of at least two cyclins which leads to inhibition of cell cycle transition and233
therefore cell cycle arrest and inhibition of proliferation.234
Overall, decreases in DNA synthesis, increases in expression of p21/p27 and decreases in expression235
of cyclin A2/D3 suggest that treatment with active VD has a strong anti-proliferative effect on muscle236
cells in culture. It is likely that the cumulative effect of all of these factors lead to an overall reduction237
in muscle cell proliferation. The process of this anti-proliferative effect of active VD is shown in238
figure 7.239
4.2. Vitamin D appears to stimulate early-stage differentiation.240
Myogenesis is a highly ordered and sequential process, guided by several transcription factors at241
various stages. This process of myogenic differentiation, and the proposed effect of active vitamin D242
on this process, is shown in figure 8. Following withdrawal from the cell cycle, as described243
previously, myoblast fusion occurs to form multinucleated myotubes [4]. MyoD is a transcription244
factor involved in the early stages of differentiation [14]. When subjected to culture conditions which245
should induce differentiation, myoD -/- cells have been shown to continue to proliferate suggesting246
that expression of myoD is essential for withdrawal from the cell cycle [29]. However, we previously247
observed no change in myoD mRNA over the time course of differentiation in C2C12 cells [21].248
Four of the five studies which measured myoD reported an increase in expression following treatment249
with active VD [4,16,20,22], although the increase in expression was not significant for one study250
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[20]. Interestingly, the only study which found a decrease in myoD expression was also the only study251
which used primary human cells [15]. This suggests that the effects of active VD on differentiation252
may depend upon cell type and/or species. However, this study also measured myoD very early in253
the process (day 1) [15] whereas the remaining four studies all reported increased myoD expression254
on either day 4 [4,16,20] or day 7 [22]. The effects observed may depend on upon the cell type and/or255
time point.256
Evidence has shown that inhibition of IGFII results in a decrease in expression of myoD target genes,257
suggesting that IGFII is a key regulator of myoD expression [30]. One of the studies which found a258
1.8-fold increase in myoD expression [22] found that both IGFI and IGFII expression also increased259
at the same time point. Additionally, increased expression of the IGFs has been shown to inhibit260
Myostatin, the only known negative regulator of muscle mass [31]. These findings suggest that active261
VD may increase expression of myoD directly or possibly indirectly via effects on local expression262
of IGFI and/or IGFII.263
4.3. Effects of vitamin D on mid-stage differentiation are cell type and time dependent.264
Induction of myogenin expression precedes the fusion of myoblasts to form myotubes, then myogenin265
switches on transcription of various muscle-specific genes (e.g. creatine kinase and MyHC isoforms)266
expressed by myotubes and muscle fibres [32]. Myogenin expression is therefore used as a marker of267
early to mid-stage differentiation and normally follows an increase in myoD expression [33]. Indeed,268
myogenin knockout mice die immediately following birth, and whilst they have myoblasts present269
within the muscle, no muscle fibres are formed, resulting in the complete absence of functional270
skeletal muscle [33]. Importantly, myogenin expression is completely blocked when the VD receptor271
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However, the nature of this effect is controversial. As seen in Figure 5, five studies reported a decrease274
in myogenin expression [14,15,17,20,24] whilst four reported an increase [4,18,22,23]. One possible275
explanation for this is the difference in methods between studies. Differentiation can be triggered via276
two mechanisms in vitro: 1. Serum starvation which leads to a decrease in mitogenic stimuli,277
withdrawal from the cell cycle and increase in myogenin expression. 2. Prolonged confluence leading278
to a high cell density and more cell-cell contacts, which leads to increased IGF expression and an279
increase in myogenin [14]. Garcia et al, 2011 [4], who used the latter method, found that myogenin280
expression was increased at day 4 following active VD treatment of C2C12 cells. On the other hand,281
Girgis et al, 2014 [14] used the serum deprivation method and reported a decrease in myogenin282
expression in C2C12 cells at day 7. It is important to note that we previously showed [21,34] using283
multiple time points, that myogenin mRNA initially increases upon induction of differentiation (via284
serum starvation) of C2C12 cells, reaching a peak around day 2-3, then decreases again. Therefore,285
induction of differentiation would be associated with an increase in myogenin mRNA at early time286
points (days 0-3), but increased differentiation could also be associated with a more rapid decline in287
expression at later time points. It is also worth noting that C2C12 cells differentiate more rapidly than288
primary human myoblasts [35] so are likely to have an earlier peak in myogenin expression. Hence,289
the discrepancies in the observed effects of active VD on myogenin expression could be due to the290
cell type used, the timepoints of measurement or a combination of the two. It is important that future291
studies should include measurements at several time points in order to make clear interpretations. It292
is also plausible that the two different methods of inducing differentiation may have different time293
frames, such that the rates of increase and decrease in expression as well as the peak of myogenin294
may be different. Certainly, there were large differences between studies in time points at which295
myogenin expression was measured, which likely contributed to the conflicting results.296
Creatine kinase (CK) is a mid-stage marker of differentiation reported to peak around day 4 to 6 in297
both C2C12 [21] and primary chick myoblasts [13]. Two studies [13,23] reported an increase in CK298
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activity following treatment with active VD both of which found expression to peak on day 2, earlier299
than the expected window of 4-6 days. The remaining study which looked at CK activity [24] reported300
a decrease in activity in C2C12 cells on day 4 across all active VD concentrations studied. Once again301
this might relate to differences in the timing relative to the expected peak in expression, with an early302
increase and a later decrease in expression potentially indicating an increase in the rate of303
differentiation.304
Overall, the data is conflicting for both markers of early to mid-stage differentiation (myogenin and305
creatine kinase), but this may be due to the varying time points that each marker was measured, the306
variation in cell type, the differing concentrations of active VD used or a combination of all three.307
4.4. Vitamin D stimulates expression of late-stage markers of differentiation.308
Myosin and the myosin heavy chain (MyHC) isoforms are muscle specific proteins that are often309
used as markers of mature, differentiated muscle cells [23] and together they form a significant310
proportion of the proteins present in differentiated muscle [36]. Five studies reported an increase in311
myosin or MyHC isoforms following active VD treatment [13,16,17,20,23] whilst two studies312
reported a decrease in expression [15,18]. We previously showed that the MyHC isoforms are313
expressed in two distinct patterns during differentiation in C2C12 cells [21]. The first pattern is an314
increase then decrease, peaking around day 2-4 of mRNA for MyHC embryonic (MyHC emb), fetal315
(MyHC neo) and slow type 1 (MyHC I) isoforms [21]. The fast type II isoforms were all expressed316
much later in differentiation, being induced at days 2-4 in the order IIa > IIx > IIb [21]. Hence, an317
increase in differentiation would always results in an increase in expression of the fast (type II)318
isoforms, but effects on the embryonic, fetal, and slow (type I) isoforms would be time dependent,319
with an increase in expression at early time points, but a decrease in expression at later time points.320
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Okuno et al, 2012 [17] found that MyHC type IIa expression in C2C12 cells was increased by active321
VD at day 8 and they suggest that this indicated an anabolic effect in muscle. On the other hand,322
Olsson et al, 2016 [15] found that both MyHC neonatal and MyHC IIa expression were reduced in323
C2C12 cells at day 1. Considering MyHC is a marker of late stage differentiation [23] it is unclear324
why this study chose to measure MyHC expression during the earlier stages of differentiation,325
possibly missing the timepoint where MyHC expression may have increased.326
The majority of in vitro evidence suggests that active VD stimulates the expression of MyHC327
isoforms, suggesting that active VD stimulates differentiation. Additionally, one study showed that328
injection of active VD increased expression of MyHC type IIa in vivo [37]. However, this could be329
due to effects on muscle fibre type rather than muscle cell differentiation. It is known that IGFI can330
alter MyHC isoform expression [16] so active VD may impact on muscle fibre type indirectly via331
induction of local IGFI expression. Supporting this, Braga et al, 2017 [22] reported an increase in332
expression of both IGFI and IGFII following active VD treatment in primary mouse cells in vitro.333
However, some argue that non-genomic actions of active VD, such as increases in intracellular334
Calcium concentrations, may be responsible for its effects on MyHC mRNA expression [38].335
4.5. Vitamin D increases myotube size336
Of the five studies which measured myotube size, all five reported an increase in myotube size337
[4,14,18,20,23], which suggests a stimulatory effect of active VD on differentiation. In addition,338
Garcia et al, 2011 [4] found an increase in expression of Follistatin (Fst). Fst is an antagonist of339
Myostatin (Mstn) a known negative regulator of muscle mass [31], including both muscle cell340
proliferation and differentiation. Therefore, active VD might increase myotube size directly and/or341
indirectly via increasing IFG1 or Fst expression, the latter then inhibits Mstn (an inhibitor of342
differentiation) but both result in increased differentiation. Supporting this, Girgis et al 2014 [14]343
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found myotube size was increased 1.8-fold on day 10 following a 10-fold decrease in Myostatin344
expression on day 7.345
5. Conclusions346
There is reasonably strong evidence to suggest that active VD inhibits proliferation of myoblasts, and347
stimulates differentiation and increases myotube size, although the effects on each stage of348
differentiation are not entirely consistent. These inconsistencies may relate to the use of different cell349
types and measurements at variable time points which makes interpretation more difficult. However,350
understanding the normal time course of expression during differentiation allows for some351
consistency across studies, but it clearly indicates that future studies should involve multiple time352
points. Also, only one study [24] used concentrations of active VD within the physiological serum353
range (around 10-10M) [39] so future studies should also consider using concentrations of active VD354
which are more physiologically relevant. However, it is worth noting that muscle cells do express 1α-355
hydroxylase and therefore can locally convert inactive VD to the active form [40]. As it is not possible356
to measure these transient, local fluctuations in active VD, it cannot be ruled out that it may be357
possible for intracellular physiological concentrations to reach levels used within some of the studies358
in this review (10-7M).359
Due to the presence of 1α-hydroxylase within skeletal muscle [40] future studies should also 360
investigate the effects of inactive VD on muscle cells to see whether this results in similar effects to361
the active form.362
It does appear that active VD has effects on skeletal muscle, particularly muscle cell proliferation and363
differentiation, indicating potential effects during embryonic development; when these processes364
mainly take place. VD deficiency has been shown to increase the risk of poor muscle strength and365
therefore falls, particularly in the elderly population [4,9], but this review suggests that VD deficiency366
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during embryonic and fetal development (i.e. during pregnancy) may also impact upon muscle367
development and function. Whilst VD supplementation in deficient individuals appears effective in368
increasing muscle strength and therefore decreasing fall risk in the elderly [24], more research is369
needed to determine the impacts of supplementation during pregnancy/lactation or in the young370
offspring on muscle cell differentiation.371
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Captions
Figure 1: Vitamin D synthesis within the body including precursors, enzymes, and body site. Images
used within this figure were obtained from smart servier medical art and can be found at
https://smart.servier.com.
Figure 2. Selection and exclusion of studies in accordance with PRISMA guidelines (Moher et al.,
2015).
Figure 3. Effect of 1,25(OH)2D3 on DNA synthesis compared to untreated cells. The active form of
vitamin D (1,25(OH)2D3) at 10-7M was used in all studies. *p<0.05, **p<0.01, ***p<0.001.
Figure 4. Effect of 1,25(OH)2D3 or analogue on MyoD mRNA expression. The active form of
vitamin D (1,25(OH)2D3) at 10-7M was used in all studies apart from Saito et al, 2017 where
Eldecalcitol (an analogue of the active form of vitamin D) was used. Black bars indicate mRNA
expression whilst grey indicates protein expression. *p<0.05, ***p<0.001.
Figure 5: Effect of 1,25(OH)2D3 of Myogenin expression. The active form of vitamin D
(1,25(OH)2D3) at 10-7M was used in all studies apart from Gili et al, 2016 where 10-8M was used.
Black bars indicate mRNA expression whilst grey indicates protein expression. *p<0.05, **p<0.01,
***p<0.001
Figure 6: Effect of 1,25(OH)2D3 on myotube size. 5 studies investigated the effect of 1,25(OH)2D3
on myotube size. Myotube size was measured at varying time points which ranged from day 3 to day
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Figure 7: Effect of active vitamin D (1,25(OH)2D3 on myoblast proliferation. Images used within
this figure were obtained from smart servier medical art and can be found at https://smart.servier.com.
Figure 8: Process of myogenic differentiation from myoblasts to multinucleated muscle fibers
showing the effect of high/sufficient active vitamin D (VD) on various transcription factors within
the process compared to low/deficient levels. Images used within this figure were obtained from smart
servier medical art and can be found at https://smart.servier.com.
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Table 1. Summary of quality assessment of included studies.
Question
Study, year 1.1 1.2 1.3 2.1 2.2 2.3 3.1 3.2 3.3 3.4 Rating
Braga, 2017           Low
Capiati, 1999           Low
Garcia, 2011           Low
Gili, 2016           Low
Girgis, 2014           Low
Okuno, 2012           Low
Olsson, 2016           Low
Romeu Montenegro, 2019          Low
Ryan, 2013           Low
Saini, 2019           Low
Saito, 2017           Low
Van der Meijden, 2016           Low
low risk of bias, moderate risk of bias, high risk of bias, no information given/not applicable
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Table 2. Summary of study characteristics383
Author, year Cell type Form of
vitamin D
Concentration Outcomes measured
Braga et al, 2017 Mouse skeletal muscle satellite cells 1,25(OH)2D3 10-7M MyoD, myogenin
Capiati et al, 1999 Chick myoblasts (obtained from 12-day-
old embryo breast tissue
1,25(OH)2D3 10-9M Proliferation, creatine kinase,
myosin
Garcia et al, 2011 C2C12 1,25(OH)2D3 10-7M MyoD, myogenin, myotube size
Gili et al, 2016 C2C12 1,25(OH)2D3 10-9M Myogenin, creatine kinase,
myosin, myotube size
Girgis et al, 2014 C2C12 1,25(OH)2D3 10-7M Myogenin, myotube size
Okuno et al, 2012 C2C12 1,25(OH)2D3 10-7M, 10-8M and 10-
9M
Myogenin, myosin




Human skeletal muscle myoblasts 1,25(OH)2D3 10-7M Proliferation, myogenin, myosin,
myotube size
Ryan et al, 2013 C2C12 1,25(OH)2D3 10-5M, 10-7M, Myogenin, creatine kinase
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Saini et al, 2019 Human skeletal muscle myoblasts 1,25(OH)2D3 10-7M, 10-9M and 10-
11M
Proliferation
Saito et al, 2017 C2C12 Eldecalcitol 10-7M, 10-8M and 10-
9M
MyoD, myosin
Van der Meijden et al,
2016
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Table 3: Effects of 1,25(OH)2D3 on proliferation
Reference
(Cell type)
VitD form and concentration Effect on proliferation Checked for
apoptosis?
Capiati et al, 2019
(Primary chick)
10-9M 1,25(OH)2D3 [3H]thymide incorporation 1.5-fold on day 1, then 0.7-fold
on day 4
Garcia et al, 2011
(C2C12)
10-7M 1,25(OH)2D3 Proliferating cell nuclear antigen (PCNA) protein 0.25-fold
on day 7
Girgis et al, 2014
(C2C12)
10-7M 1,25(OH)2D3 Proliferation 0.4-fold on day 2
23% increase in cells in G0/G1 quiescent phase on day 2
Cyclin D1 mRNA 0.75-fold on day 2

Okuno et al, 2012
(C2C12)
10-7M 1,25(OH)2D3 17% increase in cells in G0/G1 quiescent phase on day 3
P21 mRNA 2-fold on day 3
P27 mRNA 3-fold on day 3
Olsson et al, 2016
(Primary human)
10-7M 1,25(OH)2D3 BrdU incorporation 0.5-fold on day 2
Cyclin D2 mRNA down regulated 3-fold

Romeu Montenegro et al, 2019
(Primary human)
10-7M 1,25(OH)2D3 BrdU incorporation 0.7-fold on day 2
Decrease in number of cells in G2/M phase on day 2
Saini et al, 2019
(Primary human)
10-7M 1,25(OH)2D3 EdU incorporation 0.95-fold on day 2
Down regulation of cyclin A2 and D1 mRNA after 24hr
Van der Meijden et al, 2016
(C2C12)
10-7M 1,25(OH)2D3 27.6% fewer viable cells on day 4
All values reported are significant (p<0.05)
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Table 4. Effects of 1,25(OH)2D3 on Creatine Kinase Activity.
Reference
(Cell type)
VitD form and concentration CK activity Significance
Capiati et al, 1999
(Primary chick)
10-9M 1,25(OH)2D3 -45% on day 1
+55% on day 2
+30% on day 3





Gili et al, 2016
(C2C12)
10-7M 1,25(OH)2D3 1.7-fold on day 1
1.8-fold on day 2
1.3-fold on day 4
Individual p values not given.
ANOVA interaction p<0.05
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Table 5. Effects of 1,25(OH)2D3 or eldecalcitol on myosin or myosin heavy chain isoform expression
Reference
(Cell type)
VitD concentration and form Factor measured Effect Significance
Capiati et al, 1999
(Primary chick)
10-9M 1,25(OH)2D3 Myosin protein +88% on day 2
+ 31.5% on day 6
p<0.01
p<0.01
Gili et al, 2016
(C2C12)
10-9M 1,25(OH)2D3 MyHC protein 1.2-fold on day 2
1.4-fold on day 4
p values not given
Okuno et al, 2012
(C2C12)
10-7M 1,25(OH)2D3 MyHC neo mRNA
MyHCIIa mRNA
0.4-fold on day 4
2.5-fold on day 8
p<0.05
p<0.01
Olsson et al, 2016
(Primary human)
10-7M 1,25(OH)2D3 MyHC neo mRNA
MyHCIIa mRNA
0.66-fold on day 1
0.73-fold on day 1
No p values given
Romeu Montenegro et al, 2019
(Primary human)
10-7M 1,25(OH)2D3 MyHCII mRNA 0.4-fold on day 5 p<0.01
Saito et al, 2017
(C2C12)
10-8M eldecalcitol MyHC neo mRNA
MyHCIIa mRNA
1.4-fold on day 4
1.8-fold on day 4
Not significant
p<0.01
Van der Meijden et al, 2016
(C2C12)
10-7M 1,25(OH)2D3 MyHCIIa mRNA 2.5-fold on day 3 p value not given
Note: 1,25(OH)2D3, 1,25 dihydroxyvitamin D; MyHC, myosin heavy chain,
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